Zacks Investment Research on MSN10d
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies
Amgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET ...
pharmaphorum3d
Amgen pays Kyowa $400m upfront for OX40 eczema drug
The deal gives Amgen rights to the KHK4083 antibody in all countries except Kyowa's home market of Japan, and is back-loaded with potential milestone payments worth another $850 million plus ...
The Pharma Letter10d
Amgen and Kyowa Kirin announce rocatinlimab Phase III success
US biotech Amgen (Nasdaq: AMGN) and Japanese partner Kyowa Kirin (TYO: 4151) announced new results from the ongoing ROCKET ...
Amgen (AMGN) Up 2.9% Since Last Earnings Report: Can It Continue?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reuters1d
Amgen Inc
Drugmaker Amgen to invest $200 million in India site, CEO says U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further ...
Reuters24d
Drugmaker Amgen to invest $200 million in India site, CEO says
Amgen announced its plans to open a "technology ... 7:05 AM UTC · Updated ago category Berkshire raises stakes in five Japanese trading houses to near 10% 7:03 AM UTC · Updated ago Reuters ...
The Pharma Letter4d
The week in pharma: action, reaction and insight – week to March 14
The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech ...